IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Clovis Oncology, Inc. (“Clovis” or the “Company”) (NASDAQ: CLVS). Investors who purchased or otherwise acquired shares between October 31, 2013 and November 15, 2015, inclusive (the “Class Period”) are encouraged to contact the Firm prior to the January 19, 2016 lead plaintiff motion deadline.
If you purchased shares of Clovis during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company issued materially false and misleading statements to investors and/or failed to disclose that (1) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; (2) Clovis’ Breakthrough Therapy designation submission contained immature data set based primarily on unconfirmed responses; (3) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; and (4) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected. When the truth was revealed, shares dropped causing investors harm.
If you purchased shares of Clovis during the Class Period, you have until January 19, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.